glp-1 drugs kidney disease Glucagon-like Peptide Receptor Agonists and Outcomes in the Era of Personalized Medicine: Focus on Albuminuria GLP1 Receptor Agonists vs SGLT2-I
Description
Such interactions can significantly alter therapeutic outcomes and adverse effect profiles
Oncology drugs continue to be a major cost driver, with double-digit spending growth due to expensive new therapies and expanded treatments
Drug Metabolism and Disposition, 38(11), 19441953
Players are leveraging investments and expansion opportunities to capitalize on the rising demand for diabetes and obesity treatment
doi: 10.1093/ajcn/87.5.1558S
This highlights that traditional approaches to curbing the prevalence of overweight and obesity have had limited success
